Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy-Reference-Cited by-同舟云学术

Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy

Published:2021-10-21 Issue:2 Volume:63 Page:426-434
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chen Man¹^ORCID,Fu Minjing¹,Wang Aixian¹,Wu Xueying¹,Zhen Junyi¹,Gong Meiwei¹,Zhang Xian²,Yue Guanlan³,Du Qing¹,Zhao Wei³,Zhao Yanli³,Lu Peihua³,Wang Hui¹^ORCID

Affiliation:

1. Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang, China

2. Department of Haematology, Hebei Yanda Lu Daopei Hospital, Langfang, China

3. Department of Stem Cell Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1980214

Reference27 articles.

1. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

2. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities

3. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

4. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

5. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

2. Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy;Chinese Medical Journal;2023-12-26

3. 15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges;European Journal of Haematology;2023-09-14

4. Guidelines for the flow cytometric minimal residual disease monitoring in B-lineage acute lymphoblastic leukemia after CD19-directed immunotherapy;Pediatric Hematology/Oncology and Immunopathology;2023-05-12

5. Recent Developments in Application of Multiparametric Flow Cytometry in CAR-T Immunotherapy;Immune Checkpoint Inhibitors - New Insights and Recent Progress;2023-03-08